← COGNITION THERAPEUTICS INC (CGTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
COGNITION THERAPEUTICS INC (CGTX)
Biological Products, (No Diagnostic Substances) · market cap $92M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Cognition Therapeutics (CGTX) is a small-cap Alzheimer's-focused biotech with 25 employees and a ~$98M market cap trading at ~$1.09. Its lead asset CT1812 is in Phase 2 for early Alzheimer's disease, with a Phase 2 readout expected around April 2027. The company carries $31.1M cash (~17 months runway), no revenue, and an elevated dilution risk flag.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-05-31 (est.)Phase 2 · CT1812imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CT1812 | Phase 2 | Early Alzheimer's Disease |
| C105 | Phase 2 | Cognition Disorders |
| golexanolone | Phase 2 | Primary Biliary Cholangitis (PBC) |
| Active Treatment- CT1812 100 mg | Phase 2 | Alzheimer Disease |
| Dexmedetomidine | Phase 2 | Alzheimer Disease |
| CBD 100 mg/mL Oral Solution | Phase 3 | Psychosis |
Price & technical context
3-month
-23.9%
6-month
+0.0%
12-month
-34.1%
52-wk range
$0.60–$1.95
vs 50-day MA
-10.5%
vs 200-day MA
-21.7%
Realized vol
103.0%
Max drawdown
-81.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CGTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.